Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Hogan

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Haematologica|May 19, 2019
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?Miguel-Angel Perales, Benjamin Tomlinson, Mei-Jie Zhang, et al.
Blood Neoplasia|April 6, 2026
Treatment-specific prognostic performance of ELN 2022, ELN 2024, and Beat AML 2024: a real-world AML validation studyTariq Kewan, Oudai Alkabbani, Hadil Zureigat, et al.
British Journal of Haematology|July 13, 2021
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysisSameem Abedin, Nahid Rashid, Mark Schroeder, et al.
American Journal of Hematology|March 18, 2022
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blastsNaseema Gangat, Kristen McCullough, Isla Johnson, et al.
Haematologica|August 3, 2023
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemiaNaseema Gangat, Kristen McCullough, Maymona Abdelmagid, et al.
Blood Cancer Journal|June 17, 2020
A population-based study of chronic neutrophilic leukemia in the United StatesGordon J Ruan, Caleb J Smith, Courtney Day, et al.
Blood Advances|July 1, 2025
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysisEli Muchtar, Angela Dispenzieri, Francis K Buadi, et al.
Mayo Clinic Proceedings|August 6, 2019
Etiologies of Extreme Thrombocytosis: A Contemporary SeriesRonan W Hsieh, Aishwarya Ravindran, Christopher C Hook, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 16, 2018
Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple MyelomaAnkit Kansagra, Wilson I Gonsalves, Morie A Gertz, et al.
British Journal of Haematology|March 5, 2020
Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)Guadalupe Antelo, Abhishek A Mangaonkar, Giacomo Coltro, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Haematologica|May 19, 2019
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?Miguel-Angel Perales, Benjamin Tomlinson, Mei-Jie Zhang, et al.
Blood Neoplasia|April 6, 2026
Treatment-specific prognostic performance of ELN 2022, ELN 2024, and Beat AML 2024: a real-world AML validation studyTariq Kewan, Oudai Alkabbani, Hadil Zureigat, et al.
British Journal of Haematology|July 13, 2021
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysisSameem Abedin, Nahid Rashid, Mark Schroeder, et al.
American Journal of Hematology|March 18, 2022
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blastsNaseema Gangat, Kristen McCullough, Isla Johnson, et al.
Haematologica|August 3, 2023
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemiaNaseema Gangat, Kristen McCullough, Maymona Abdelmagid, et al.
Blood Cancer Journal|June 17, 2020
A population-based study of chronic neutrophilic leukemia in the United StatesGordon J Ruan, Caleb J Smith, Courtney Day, et al.
Blood Advances|July 1, 2025
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysisEli Muchtar, Angela Dispenzieri, Francis K Buadi, et al.
Mayo Clinic Proceedings|August 6, 2019
Etiologies of Extreme Thrombocytosis: A Contemporary SeriesRonan W Hsieh, Aishwarya Ravindran, Christopher C Hook, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 16, 2018
Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple MyelomaAnkit Kansagra, Wilson I Gonsalves, Morie A Gertz, et al.
British Journal of Haematology|March 5, 2020
Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)Guadalupe Antelo, Abhishek A Mangaonkar, Giacomo Coltro, et al.
Pageof 11